Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $20.00.

A number of equities analysts recently weighed in on the company. Rodman & Renshaw cut Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Robert W. Baird dropped their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Stifel Nicolaus decreased their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, Wedbush downgraded shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd.

Alto Neuroscience Stock Down 4.8 %

Shares of NYSE:ANRO opened at $4.39 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The stock’s 50-day moving average price is $4.15 and its two-hundred day moving average price is $9.17. Alto Neuroscience has a 12-month low of $3.56 and a 12-month high of $24.00.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. As a group, equities analysts expect that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its holdings in Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after acquiring an additional 3,715 shares in the last quarter. Rhumbline Advisers acquired a new position in Alto Neuroscience in the second quarter valued at about $113,000. Jane Street Group LLC bought a new stake in Alto Neuroscience during the third quarter worth about $124,000. Federated Hermes Inc. lifted its holdings in shares of Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after acquiring an additional 3,000 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in shares of Alto Neuroscience during the 3rd quarter worth approximately $146,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.